drugset / Trial / NCT00219167
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
RandomizedParallel-groupDouble-blindTreatment
Summary
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks
Timeline
- Start
- 2005-04
- Primary completion
- 2006-02
- Completion
- 2006-02
Publications
- Results Verdecchia P, Calvo C, Mockel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press. 2007;16(6):381-91. doi: 10.1080/08037050701717014.
- Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 75 mg | Oral |
| Subject | Aliskiren | Small molecule | 150 mg | Oral |
| Subject | Aliskiren | Small molecule | 300 mg | Oral |